TL;DR: In the cagrilintide dose-finding literature, the once-weekly amount is escalated slowly rather than started at target, stepping up roughly every four weeks through the studied levels (0.3, 0.6, 1.2, 2.4, and 4.5 mg in the phase 2 trial). Nausea tends to peak in the days after each step-up and settle as the body adapts at a stable dose, and the weight effect largely flattens at the top of the range. This is a summary of published research protocols, not human-dosing guidance.
Cagrilintide is a long-acting amylin analog, and searches for how it is dosed on its own — separate from the CagriSema combination — have been climbing as Novo Nordisk’s combination filing moves through review. The question behind those searches is the same one that comes up for every incretin-adjacent peptide: what does the weekly step-up ladder actually look like in the trials, and why does the literature insist on climbing gradually instead of starting at the effective amount? This article summarizes the documented escalation pattern, where gastrointestinal effects cluster, and the pharmacology that makes a slow ramp the standard research design. For the mechanism and background overview, see what cagrilintide is; this piece is the dosing and titration companion.
Why amylin agonism needs a ramp
Cagrilintide is a dual amylin and calcitonin receptor agonist, and that receptor system is what makes titration relevant. Amylin is co-secreted with insulin at meals and acts as a satiety signal: it slows gastric emptying, promotes fullness through hindbrain and hypothalamic pathways, and dampens the drive to eat. Those are the effects a researcher is trying to isolate — and they are also the source of the early tolerability problems, because a stomach that empties more slowly is a stomach more prone to nausea.
Critically, this is a different receptor system from GLP-1. Semaglutide and cagrilintide both slow gastric emptying and blunt appetite, but they arrive there through distinct receptors, which is the whole rationale for pairing them. For titration, though, the practical consequence is identical to the GLP-1 story: an agonist that acts on gut motility and central nausea pathways needs a gradual introduction so those pathways can accommodate before the amount climbs.
The long half-life — reported in the pharmacokinetic literature in the range of roughly 159 to 195 hours, or about seven to eight days — is what makes once-weekly administration feasible in the first place. It is also a second reason the ramp matters. Because the compound clears slowly, each weekly administration overlaps the previous one, and plasma exposure keeps building for several weeks before it plateaus at a given amount. Introducing a high dose immediately would mean exposure climbing for the better part of a month with no adaptation window in between.
The titration ladder in the trials
The foundational monotherapy dataset is Lau and colleagues (2021), a randomised, double-blind, placebo- and active-controlled dose-finding phase 2 trial in The Lancet, in participants with overweight or obesity and without diabetes. It studied once-weekly cagrilintide across five levels — 0.3, 0.6, 1.2, 2.4, and 4.5 mg — over a 26-week treatment period that included an initial dose-escalation phase rather than starting participants at their assigned target.
The pattern that recurs across the program, and the one the combination phase 3 work carried forward, is a slow climb: begin low, then step up roughly every four weeks through the ladder toward the assigned maintenance amount. The specific levels above are what the phase 2 trial reported; the roughly four-weekly spacing reflects the escalation design used to reach the higher assigned doses without front-loading the tolerability burden.
- 1
Low starting step
Begin well below the target amount; this initiation step is about adaptation, not effect.
- 2
Step up ~every 4 weeks
Climb through the studied levels (0.3, 0.6, 1.2, 2.4 mg), letting exposure stabilise at each before the next increase.
- 3
Nausea peaks after each step
Gastrointestinal effects cluster in the days following a step-up, then ease as the body adapts at a stable dose.
- 4
Reach assigned maintenance
Hold at the target amount; in phase 2 this ranged up to 4.5 mg, though benefit flattened toward the top.
Two features of the design are worth flagging. First, the low opening step is an initiation amount, used to begin adaptation — it is not treated as the effective target on its own. Second, the four-week spacing is not arbitrary: it approximates the time exposure needs to approach steady state at each level, so the gut adapts to a stable amount rather than one that is still rising. This is the same escalation philosophy documented for semaglutide titration, applied to a different receptor system.
Where the nausea peaks
Across the program, gastrointestinal events — nausea foremost — were the most common adverse events, and they were concentrated during dose escalation rather than at steady state. The dose-response in the phase 2 data is clear: nausea was reported by roughly a fifth of participants at the lowest 0.3 mg level and climbed toward roughly half at the highest 4.5 mg level. The higher the assigned amount, the more the ramp mattered.
The timing is the useful part. Nausea tends to spike in the days immediately following each step-up, then fade as the body accommodates at that stable amount, with most of the early titration-phase nausea easing over the following weeks at a held dose. That is exactly why a slower ramp is the standard design: each step is a small, absorbable increment, and the adaptation window between steps is where tolerability is won or lost.
For how these effects are characterized and managed in the incretin literature more broadly — the overlap is substantial, since both drive satiety through gastric and central pathways — see the GLP-1 side-effect management overview.
Diminishing returns at the top
One observation from the dose-finding work shapes how the ladder is read. The highest studied amount, 4.5 mg weekly, did not clearly outperform 2.4 mg on weight loss, while it did carry more nausea. On a benefit-versus-tolerability basis, 2.4 mg emerged as the amount taken forward into the combination program, and it is the cagrilintide component dose that anchors CagriSema.
The practical reading is that the dose-response curve appears to flatten toward the top of the studied range: pushing past the mid-range buys diminishing additional effect while the gastrointestinal cost keeps rising. This mirrors a recurring theme across satiety peptides — more is not linearly better, and the ceiling is often set by tolerability rather than by a lack of receptor headroom. It is also part of why researchers describe the ramp as a means to reach a tolerable effective amount, not the highest possible one.
Solo titration versus the CagriSema combination
Cagrilintide is studied two ways, and the titration logic differs between them. As monotherapy, the weekly amount is escalated on its own ladder, which is what isolates the amylin contribution — useful for characterising the pathway’s satiety and tolerability profile without the confound of a co-administered GLP-1. As part of CagriSema, cagrilintide is delivered in a fixed-ratio co-formulation with semaglutide, where the labeled mass refers to combined peptide content and the two components escalate together rather than being titrated independently.
That distinction matters for anyone reading a monotherapy schedule and a combination schedule side by side: they are not interchangeable. The solo ladder is designed around one receptor system’s tolerability; the combination stacks two satiety mechanisms on the same weekly cadence. For the combination background, see what CagriSema is, and for how amylin analogs sit within their broader class — including the emerging comparison with petrelintide — the amylin analogs explained overview gives the wider map. Researchers also pair amylin agonists with other incretins outside the Novo combination, a design explored in the cagri-reta stack piece.
Reconstitution and handling basics
Cagrilintide is typically supplied as a lyophilized powder that is reconstituted with bacteriostatic water before use in a laboratory context. Because the ladder deals in fractions of a milligram, the arithmetic linking vial mass, diluent volume, and draw volume is where errors creep in, so the concentration is usually worked out before the first administration rather than improvised. General handling points — bringing the vial to room temperature, adding diluent slowly down the vial wall, swirling rather than shaking, and refrigerating the reconstituted solution — are covered in technique-level detail in the peptide reconstitution guide.
Honest evidence framing
It is worth being clear about the stage of the evidence. Cagrilintide monotherapy remains investigational: the human data are largely dose-finding — pharmacokinetics, dose-response, and tolerability over weeks to months — rather than long-term outcomes. The most mature outcome data attach to the CagriSema combination, not to standalone cagrilintide. So the titration ladder summarized here rests on genuine randomised human trials, which is more than can be said for many research peptides, but the monotherapy record is still shallower and shorter than the semaglutide one. None of the amounts or schedules above should be read as instructions for use in humans; they are a description of how the compound has been studied.
Frequently asked questions
What is the cagrilintide titration ladder in the trials?
In the phase 2 dose-finding trial (Lau and colleagues, 2021), once-weekly cagrilintide was studied across 0.3, 0.6, 1.2, 2.4, and 4.5 mg, reached through a gradual dose-escalation phase rather than started at target. The recurring pattern is a low opening step followed by increases roughly every four weeks toward the assigned amount, so exposure stabilises at each level before the next increase.
Why does cagrilintide need to be titrated slowly?
Because it is an amylin-receptor agonist that slows gastric emptying and acts on central nausea and satiety pathways, and because its roughly seven-to-eight-day half-life means exposure keeps building for weeks at a fixed amount. A gradual ramp keeps each increment small and gives the gut a stable window to adapt, which is where the trial data show gastrointestinal effects are best contained.
When does nausea peak on cagrilintide?
In the trial data, nausea clustered in the days following each dose step-up and then eased as the body adapted at a stable amount. It was more common at higher assigned doses — reported by roughly a fifth of participants at the lowest level and closer to half at the highest — which is precisely why the escalation is spaced out rather than compressed.
Is a higher cagrilintide dose always better?
Not in the dose-finding data. The highest studied amount, 4.5 mg weekly, did not clearly outperform 2.4 mg on weight loss while carrying more nausea, and 2.4 mg was the amount taken forward on a benefit-versus-tolerability basis. The dose-response appears to flatten toward the top of the studied range, so the ceiling is set more by tolerability than by additional effect.
How does solo cagrilintide titration differ from CagriSema?
As monotherapy, cagrilintide is escalated on its own ladder, which isolates the amylin effect. In CagriSema it is delivered in a fixed-ratio co-formulation with semaglutide, so the two components escalate together on one weekly cadence and the labeled mass reflects combined peptide content. The two schedules are not interchangeable.
References
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021;398(10317):2160-2172.
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet. 2021;397(10286):1736-1748.
- Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet. 2023;402(10403):720-730.
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications. 2025.
Research use only. This article is an educational summary of published cagrilintide pharmacology and trial protocols. It is not medical advice and contains no therapeutic or human-dosing recommendations. Cagrilintide is discussed here solely as a research compound for laboratory and reference purposes.